Kremer G J, Atzpodien W, Schnellbacher E
Klin Wochenschr. 1975 Jul 1;53(13):637-8. doi: 10.1007/BF01469685.
In diabetic patients with hyperlipoproteinemia type IV the monohexosyl ceramide concentration in blood plasma is significantly elevated. This augmentation can be attributed to an increased monohexosyl ceramide content of the BLDL plasma fraction. In contrast, the di-, tri-, the tetrahexosyl ceramide levels remain within normal limits. In normolipidemic diabetics of comparable age, sex, and weight classes and of comparable metabolic control no elevations of glycolipid fractions could be found. However, patients with primary hyperlipoproteinemia type IV show an increase of monohexosyl ceramide concentrations in blood plasma. Therefore, the augmentation of monohexosyl ceramide levels in plasma of hyperlipidemic diabetic patients seems rather a metabolic consequence of hyperlipoproteinemia than of diabetes per se. A clearcut explantation for the monohexosyl ceramide elevations in the studied groups cannot be given at present time.
在患有IV型高脂蛋白血症的糖尿病患者中,血浆中单己糖神经酰胺浓度显著升高。这种升高可归因于极低密度脂蛋白(VLDL)血浆部分中单己糖神经酰胺含量的增加。相比之下,二己糖、三己糖、四己糖神经酰胺水平仍在正常范围内。在年龄、性别、体重类别及代谢控制相当的正常血脂糖尿病患者中,未发现糖脂组分升高。然而,原发性IV型高脂蛋白血症患者血浆中单己糖神经酰胺浓度升高。因此,高脂血症糖尿病患者血浆中单己糖神经酰胺水平的升高似乎更多是高脂蛋白血症的代谢后果,而非糖尿病本身所致。目前尚无法对研究组中单己糖神经酰胺升高给出明确解释。